About Monogenic Pharmaceuticals
MONOGENIC Pharmaceuticals is a spin-off from the laboratory of Cellular and Molecular Biology at the Montreal Heart Institute primarily developing innovative and disruptive orally available small molecules to control atherosclerotic cardiovascular disease (ASCVD) by helping the body to clear excess LDL-Cholesterol.

About the Montreal Heart Institute (Institutional partner)
Founded in 1954 by Dr. Paul David, the Montreal Heart Institute (MHI) is an ultraspecialized hospital centre dedicated to care, research, teaching, prevention, rehabilitation and the assessment of new technologies in cardiology. Its internationally recognized Research Centre was the first one entirely dedicated to cardiovascular disease and to this day remains one of the world’s best cardiology research facilities. As a division of the MHI, the Montreal Health Innovations Coordinating Center (MHICC) is a full service clinical academic research organization, providing services to the academic community and to the pharmaceutical, biotechnology and medical device industries, in the fields of cardiology, neurology, oncology, dermatology, endocrinology and pharmacogenomics. The MHICC’s flexible, dynamic and fully integrated range of services can handle all Phase II to IV clinical research needs, surpass all regulatory requirements and meet enrolment targets.

MONOGENIC Pharmaceuticals is currently seeking for private partners to complete with our Angel Investors a Series A in support to finalize our R&D Program (pre-IND up to Phase 1) with interest in advancing to and completion of Phase 2.